Trials / Completed
CompletedNCT05932446
A Study to Compare Two Formulations of LY3819469 in Healthy Participants
A Single Dose Study to Assess the Pharmacokinetics of 2 Formulations of LY3819469 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to assess two formulations of LY3819469 based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3819469 will also be evaluated. Screening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening and follow-up periods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3819469 | Administered SC. |
Timeline
- Start date
- 2023-06-30
- Primary completion
- 2023-11-07
- Completion
- 2023-11-07
- First posted
- 2023-07-06
- Last updated
- 2024-01-05
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05932446. Inclusion in this directory is not an endorsement.